Established safety profile


AEs (≥10%) from any cause reported in PALOMA-2 (as-treated population)2


Adapted from Finn RS, et al. 2016.2

Grading according to CTCAE 4.0. Data cut-off date: February 26, 2016.
*Categorised according to the MedDRA preferred terms.2 Febrile neutropenia was reported in 1.8% of patients in the IBRANCE® + letrozole group and in no patients in the placebo + letrozole group.2 ‡In the IBRANCE® + letrozole group, 30.2% of patients had Grade 1 alopecia and 2.7% had Grade 2. In the placebo + letrozole group, 14.9% of patients had Grade 1 alopecia and 0.9% had Grade 2.2

AE = adverse event; CTCAE = Common Terminology Criteria for Adverse Events; LET = letrozole; MedDRA = Medical Dictionary for Regulatory Activity; n = number of patients; PLA = placebo.

  1. IBRANCE® Summary of Product Characteristics.
  2. Finn RS, et al. N Engl J Med. 2016;375(20):1925-1936.


©2020 Pfizer. All rights reserved. PP-IBR-IRL-0501 Date of Preparation: March 2022 Legal Category: S1A